EUROPE BIOCHIPS MARKET FORECAST 2018-2026
KEY FINDINGS
Europe Biochips market stood at $2985 million in 2017. By the end of the forecast period of 2018-2026, the market is anticipated to collect $14941 million, exhibiting a CAGR of 20.06%.
MARKET INSIGHTS
The biochips market in Europe is driven by government funding to develop and promote the biotechnology sector. Also, factors like increased government funding to develop personalized medicine and rising prevalence of various government initiatives supporting biotechnology are positively influencing the growth of the biochips market in Europe. The German biochips market is being propelled by various government initiatives and programs to develop and promote biotechnology. On the other hand, the U.K biochip market finds several applications in molecular diagnostics, and in point-of-care diagnosis. France biochips market is mainly driven by funding supporting emerging fields such as cancer biomarkers, genomic studies and rise in diagnosis & treatment of cancer, while the Italian market is driven by rising investments in personalized medicines and genomics.
COMPETITIVE INSIGHTS
Some of the competing players in this market are Thermo Fisher Scientific Inc, Agilent Technology Inc, Merck Gmbh, Biochain Institute Inc, Origene Technologies Inc, Cepheid Inc, Perkinelmer Inc, Bio-Rad Laboratories Inc, Illumina Inc, Biomerieux SA, Gamida For Life Group and Cybrdi Inc.
Europe Biochips market stood at $2985 million in 2017. By the end of the forecast period of 2018-2026, the market is anticipated to collect $14941 million, exhibiting a CAGR of 20.06%.
MARKET INSIGHTS
The biochips market in Europe is driven by government funding to develop and promote the biotechnology sector. Also, factors like increased government funding to develop personalized medicine and rising prevalence of various government initiatives supporting biotechnology are positively influencing the growth of the biochips market in Europe. The German biochips market is being propelled by various government initiatives and programs to develop and promote biotechnology. On the other hand, the U.K biochip market finds several applications in molecular diagnostics, and in point-of-care diagnosis. France biochips market is mainly driven by funding supporting emerging fields such as cancer biomarkers, genomic studies and rise in diagnosis & treatment of cancer, while the Italian market is driven by rising investments in personalized medicines and genomics.
COMPETITIVE INSIGHTS
Some of the competing players in this market are Thermo Fisher Scientific Inc, Agilent Technology Inc, Merck Gmbh, Biochain Institute Inc, Origene Technologies Inc, Cepheid Inc, Perkinelmer Inc, Bio-Rad Laboratories Inc, Illumina Inc, Biomerieux SA, Gamida For Life Group and Cybrdi Inc.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. DNA CHIPS ACCOUNTS FOR THE LARGEST REVENUE SHARE OF THE BIOCHIPS MARKET BY TYPE SEGMENT
3.2.2. HOSPITALS & DIAGNOSTICS CENTERS – KEY END USER VERTICAL
3.2.3. PROTEIN CHIP IN THE TYPE SEGMENT IS PROJECTED TO RISE WITH THE HIGHEST GROWTH RATE
4. MARKET DYNAMICS
4.1. PARENT MARKET ANALYSIS: GENOMICS AND PROTEOMICS MARKET
4.2. ETYMOLOGY OF BIOCHIPS MARKET
4.3. MARKET DEFINITION & SCOPE
4.4. DRIVERS
4.4.1. INCREASING PREVALENCE OF CANCER
4.4.2. INCREASED GOVERNMENT FUNDING, R&D INVESTMENT IN BIOTECHNOLOGY
4.4.3. GROWING INTEREST IN PERSONALIZED MEDICINES
4.4.4. SIGNIFICANT GROWTH IN THE HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES
4.5. RESTRAINTS
4.5.1. LACK OF HEALTHCARE COVERAGE
4.5.2. AVAILABILITY OF ALTERNATIVE TECHNOLOGY: NEXT GENERATION SEQUENCING (NGS) TECHNOLOGY
4.5.3. LACK OF AWARENESS ABOUT BIOCHIP TECHNOLOGY
4.6. OPPORTUNITIES
4.6.1. TECHNOLOGICAL ADVANCEMENT IN BIOTECHNOLOGY
4.6.2. GROWING APPLICATIONS OF BIOCHIPS
4.7. CHALLENGES
4.7.1. COMPLEXITY OF BIOLOGICAL SYSTEMS
4.7.2. LACK OF COMMON REGULATORY STANDARDS
4.7.3. HIGH INSTRUMENTATION COST
5. MARKET BY TYPE
5.1. DNA CHIPS
5.1.1. AGRICULTURAL BIOTECHNOLOGY
5.1.2. CANCER DIAGNOSTICS & TREATMENT
5.1.3. DRUG DISCOVERY
5.1.4. GENE EXPRESSION
5.1.5. GENOMICS
5.1.6. SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING
5.1.7. OTHER DNA CHIPS
5.2. LAB ON A CHIP
5.2.1. CLINICAL DIAGNOSTICS
5.2.2. DRUG DISCOVERY
5.2.3. GENOMICS
5.2.4. POINT OF CARE (POC) & IN VITRO DIAGNOSIS (IVS)
5.2.5. PROTEOMICS
5.2.6. OTHER LAB ON A CHIP
5.3. PROTEIN CHIPS
5.3.1. DIAGNOSTICS
5.3.2. DRUG DISCOVERY
5.3.3. EXPRESSION PROFILING
5.3.4. HIGH THROUGHPUT SCREENING
5.3.5. PROTEOMICS
5.3.6. OTHER PROTEIN CHIPS
5.4. OTHER CHIPS
5.4.1. CELL ARRAYS
5.4.2. TISSUE ARRAYS
6. MARKET BY SUBSTRATE MATERIALS
6.1. GLASS
6.2. POLYMERS
6.3. SILICON
6.4. OTHER SUBSTRATE MATERIALS
7. MARKET BY END USERS
7.1. BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES
7.2. HOSPITALS AND DIAGNOSTICS CENTERS
7.3. ACADEMIC AND RESEARCH INSTITUTE
8. KEY ANALYTICS
8.1. PORTER’S FIVE FORCE MODEL
8.1.1. THREAT OF NEW ENTRANTS
8.1.2. THREAT OF SUBSTITUTE
8.1.3. BARGAINING POWER OF SUPPLIERS
8.1.4. BARGAINING POWER OF BUYERS
8.1.5. THREAT OF COMPETITIVE RIVALRY
8.2. OPPORTUNITY MATRIX
8.3. VENDOR LANDSCAPE
8.4. VALUE CHAIN ANALYSIS
8.4.1. RESEARCH & DEVELOPMENT
8.4.2. RAW MATERIALS
8.4.3. MANUFACTURING
8.4.4. WHOLESALERS/RETAILERS/DISTRIBUTORS
8.4.5. END USERS
8.5. LEGAL, POLICY & REGULATORY FRAMEWORK
8.6. KEY BUYING CRITERIA
8.6.1. COST
8.6.2. APPLICATIONS
8.6.3. PRODUCT TYPE
8.7. INVESTMENT ANALYSIS
8.7.1. OPPORTUNITIES BY END-USER SEGMENT
8.7.2. OPPORTUNITIES BY BIOCHIP TYPE SEGMENT
9. GEOGRAPHICAL ANALYSIS
9.1. GERMANY
9.2. UNITED KINGDOM
9.3. FRANCE
9.4. ITALY
9.5. SPAIN
9.6. REST OF EUROPE
10. COMPETITIVE LANDSCAPE
10.1. MARKET SHARE ANALYSIS
10.2. KEY COMPANY ANALYSIS
10.2.1. MERCK GMBH
10.2.2. AGILENT TECHNOLOGY INC.
10.2.3. ILLUMINA INC.
10.2.4. THERMO FISHER SCIENTIFIC INC.
10.3. CORPORATE STRATEGIES
10.3.1. PARTNERSHIP & COLLABORATION
10.3.2. MERGERS AND ACQUISITIONS
10.4. COMPANY PROFILES
10.4.1. AGILENT TECHNOLOGY INC.
10.4.2. BIOCHAIN INSTITUTE INC.
10.4.3. BIOMERIEUX SA
10.4.4. BIO-RAD LABORATORIES INC.
10.4.5. CEPHEID INC.
10.4.6. CYBRDI INC.
10.4.7. FLUIDIGM CORPORATION
10.4.8. GAMIDA FOR LIFE GROUP
10.4.9. ILLUMINA INC.
10.4.10. IMGENEX
10.4.11. MERCK GMBH
10.4.12. ORIGENE TECHNOLOGIES INC.
10.4.13. PERKINELMER INC.
10.4.14. SAMSUNG ELECTRONICS INC.
10.4.15. THERMO FISHER SCIENTIFIC INC.
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. DNA CHIPS ACCOUNTS FOR THE LARGEST REVENUE SHARE OF THE BIOCHIPS MARKET BY TYPE SEGMENT
3.2.2. HOSPITALS & DIAGNOSTICS CENTERS – KEY END USER VERTICAL
3.2.3. PROTEIN CHIP IN THE TYPE SEGMENT IS PROJECTED TO RISE WITH THE HIGHEST GROWTH RATE
4. MARKET DYNAMICS
4.1. PARENT MARKET ANALYSIS: GENOMICS AND PROTEOMICS MARKET
4.2. ETYMOLOGY OF BIOCHIPS MARKET
4.3. MARKET DEFINITION & SCOPE
4.4. DRIVERS
4.4.1. INCREASING PREVALENCE OF CANCER
4.4.2. INCREASED GOVERNMENT FUNDING, R&D INVESTMENT IN BIOTECHNOLOGY
4.4.3. GROWING INTEREST IN PERSONALIZED MEDICINES
4.4.4. SIGNIFICANT GROWTH IN THE HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES
4.5. RESTRAINTS
4.5.1. LACK OF HEALTHCARE COVERAGE
4.5.2. AVAILABILITY OF ALTERNATIVE TECHNOLOGY: NEXT GENERATION SEQUENCING (NGS) TECHNOLOGY
4.5.3. LACK OF AWARENESS ABOUT BIOCHIP TECHNOLOGY
4.6. OPPORTUNITIES
4.6.1. TECHNOLOGICAL ADVANCEMENT IN BIOTECHNOLOGY
4.6.2. GROWING APPLICATIONS OF BIOCHIPS
4.7. CHALLENGES
4.7.1. COMPLEXITY OF BIOLOGICAL SYSTEMS
4.7.2. LACK OF COMMON REGULATORY STANDARDS
4.7.3. HIGH INSTRUMENTATION COST
5. MARKET BY TYPE
5.1. DNA CHIPS
5.1.1. AGRICULTURAL BIOTECHNOLOGY
5.1.2. CANCER DIAGNOSTICS & TREATMENT
5.1.3. DRUG DISCOVERY
5.1.4. GENE EXPRESSION
5.1.5. GENOMICS
5.1.6. SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING
5.1.7. OTHER DNA CHIPS
5.2. LAB ON A CHIP
5.2.1. CLINICAL DIAGNOSTICS
5.2.2. DRUG DISCOVERY
5.2.3. GENOMICS
5.2.4. POINT OF CARE (POC) & IN VITRO DIAGNOSIS (IVS)
5.2.5. PROTEOMICS
5.2.6. OTHER LAB ON A CHIP
5.3. PROTEIN CHIPS
5.3.1. DIAGNOSTICS
5.3.2. DRUG DISCOVERY
5.3.3. EXPRESSION PROFILING
5.3.4. HIGH THROUGHPUT SCREENING
5.3.5. PROTEOMICS
5.3.6. OTHER PROTEIN CHIPS
5.4. OTHER CHIPS
5.4.1. CELL ARRAYS
5.4.2. TISSUE ARRAYS
6. MARKET BY SUBSTRATE MATERIALS
6.1. GLASS
6.2. POLYMERS
6.3. SILICON
6.4. OTHER SUBSTRATE MATERIALS
7. MARKET BY END USERS
7.1. BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES
7.2. HOSPITALS AND DIAGNOSTICS CENTERS
7.3. ACADEMIC AND RESEARCH INSTITUTE
8. KEY ANALYTICS
8.1. PORTER’S FIVE FORCE MODEL
8.1.1. THREAT OF NEW ENTRANTS
8.1.2. THREAT OF SUBSTITUTE
8.1.3. BARGAINING POWER OF SUPPLIERS
8.1.4. BARGAINING POWER OF BUYERS
8.1.5. THREAT OF COMPETITIVE RIVALRY
8.2. OPPORTUNITY MATRIX
8.3. VENDOR LANDSCAPE
8.4. VALUE CHAIN ANALYSIS
8.4.1. RESEARCH & DEVELOPMENT
8.4.2. RAW MATERIALS
8.4.3. MANUFACTURING
8.4.4. WHOLESALERS/RETAILERS/DISTRIBUTORS
8.4.5. END USERS
8.5. LEGAL, POLICY & REGULATORY FRAMEWORK
8.6. KEY BUYING CRITERIA
8.6.1. COST
8.6.2. APPLICATIONS
8.6.3. PRODUCT TYPE
8.7. INVESTMENT ANALYSIS
8.7.1. OPPORTUNITIES BY END-USER SEGMENT
8.7.2. OPPORTUNITIES BY BIOCHIP TYPE SEGMENT
9. GEOGRAPHICAL ANALYSIS
9.1. GERMANY
9.2. UNITED KINGDOM
9.3. FRANCE
9.4. ITALY
9.5. SPAIN
9.6. REST OF EUROPE
10. COMPETITIVE LANDSCAPE
10.1. MARKET SHARE ANALYSIS
10.2. KEY COMPANY ANALYSIS
10.2.1. MERCK GMBH
10.2.2. AGILENT TECHNOLOGY INC.
10.2.3. ILLUMINA INC.
10.2.4. THERMO FISHER SCIENTIFIC INC.
10.3. CORPORATE STRATEGIES
10.3.1. PARTNERSHIP & COLLABORATION
10.3.2. MERGERS AND ACQUISITIONS
10.4. COMPANY PROFILES
10.4.1. AGILENT TECHNOLOGY INC.
10.4.2. BIOCHAIN INSTITUTE INC.
10.4.3. BIOMERIEUX SA
10.4.4. BIO-RAD LABORATORIES INC.
10.4.5. CEPHEID INC.
10.4.6. CYBRDI INC.
10.4.7. FLUIDIGM CORPORATION
10.4.8. GAMIDA FOR LIFE GROUP
10.4.9. ILLUMINA INC.
10.4.10. IMGENEX
10.4.11. MERCK GMBH
10.4.12. ORIGENE TECHNOLOGIES INC.
10.4.13. PERKINELMER INC.
10.4.14. SAMSUNG ELECTRONICS INC.
10.4.15. THERMO FISHER SCIENTIFIC INC.
LIST OF TABLES
TABLE 1: EUROPE BIOCHIPS MARKET, BY GEOGRAPHY, 2018-2026 (IN $ MILLION)
TABLE 2: NOTABLE INVESTMENTS MADE IN BIOTECHNOLOGY INDUSTRY IN 2017
TABLE 3: EUROPE BIOCHIPS MARKET, BY TYPE, 2018-2026, (IN $ MILLION)
TABLE 4: EUROPE DNA CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 5: EUROPE LAB ON A CHIP MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 6: EUROPE PROTEIN CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 7: EUROPE OTHER CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 8: EUROPE BIOCHIPS MARKET, BY SUBSTRATE MATERIALS, 2018-2026 (IN $ MILLIONS)
TABLE 9: PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS
TABLE 10: EUROPE BIOCHIPS MARKET, BY END USERS, 2018-2026 (IN $ MILLIONS)
TABLE 11: OPPORTUNITY MATRIX FOR BIOCHIPS MARKET
TABLE 12: VENDOR LANDSCAPE OF BIOCHIPS MARKET
TABLE 13: LEGAL, POLICY & REGULATORY FRAMEWORK OF BIOCHIPS MARKET
TABLE 14: EUROPE BIOCHIPS MARKET, BY COUNTRY, 2018-2026 (IN $ MILLION)
TABLE 15: LIST OF PARTNERSHIP & COLLABORATION
TABLE 16: LIST OF MERGERS AND ACQUISITIONS
TABLE 1: EUROPE BIOCHIPS MARKET, BY GEOGRAPHY, 2018-2026 (IN $ MILLION)
TABLE 2: NOTABLE INVESTMENTS MADE IN BIOTECHNOLOGY INDUSTRY IN 2017
TABLE 3: EUROPE BIOCHIPS MARKET, BY TYPE, 2018-2026, (IN $ MILLION)
TABLE 4: EUROPE DNA CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 5: EUROPE LAB ON A CHIP MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 6: EUROPE PROTEIN CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 7: EUROPE OTHER CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 8: EUROPE BIOCHIPS MARKET, BY SUBSTRATE MATERIALS, 2018-2026 (IN $ MILLIONS)
TABLE 9: PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS
TABLE 10: EUROPE BIOCHIPS MARKET, BY END USERS, 2018-2026 (IN $ MILLIONS)
TABLE 11: OPPORTUNITY MATRIX FOR BIOCHIPS MARKET
TABLE 12: VENDOR LANDSCAPE OF BIOCHIPS MARKET
TABLE 13: LEGAL, POLICY & REGULATORY FRAMEWORK OF BIOCHIPS MARKET
TABLE 14: EUROPE BIOCHIPS MARKET, BY COUNTRY, 2018-2026 (IN $ MILLION)
TABLE 15: LIST OF PARTNERSHIP & COLLABORATION
TABLE 16: LIST OF MERGERS AND ACQUISITIONS
LIST OF FIGURES
FIGURE 1: EUROPE BIOCHIPS MARKET, BY END USERS, 2017 & 2026 (IN %)
FIGURE 2: EVOLUTION & TRANSITION OF BIOCHIPS
FIGURE 3: WORLDWIDE HEALTHCARE SPENDING, BY REGIONS, 2014-2015 (% OF GDP)
FIGURE 4: COMPARISON OF HEALTHCARE SPENDING PER CAPITA AND OUT OF THE POCKET HEALTH EXPENDITURE
FIGURE 5: EUROPE BIOCHIPS MARKET, BY DNA CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 6: EUROPE DNA CHIPS MARKET, BY AGRICULTURAL BIOTECHNOLOGY, 2018-2026 (IN $ MILLION)
FIGURE 7: EUROPE DNA CHIPS MARKET, BY CANCER DIAGNOSTICS & TREATMENT, 2018-2026 (IN $ MILLION)
FIGURE 8: EUROPE DNA CHIPS MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 9: EUROPE DNA CHIPS MARKET, BY GENE EXPRESSION, 2018-2026 (IN $ MILLION)
FIGURE 10: EUROPE DNA CHIPS MARKET, BY GENOMICS, 2018-2026 (IN $ MILLION)
FIGURE 11: EUROPE DNA CHIPS MARKET, BY SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING, 2018-2026 (IN $ MILLION)
FIGURE 12: EUROPE DNA CHIPS MARKET, BY OTHER CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 13: EUROPE BIOCHIPS MARKET, BY LAB ON A CHIP, 2018-2026 (IN $ MILLION)
FIGURE 14: EUROPE LAB ON A CHIP MARKET, BY CLINICAL DIAGNOSTICS, 2018-2026 (IN $ MILLION)
FIGURE 15: EUROPE LAB ON A CHIP MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 16: EUROPE LAB ON A CHIP MARKET, BY GENOMICS, 2018-2026 (IN $ MILLION)
FIGURE 17: EUROPE LAB ON A CHIP MARKET, BY POINT OF CARE (POC) & IN VITRO DIAGNOSIS (IVS), 2018-2026 (IN $ MILLION)
FIGURE 18: EUROPE LAB ON A CHIP MARKET, BY PROTEOMICS, 2018-2026 (IN $ MILLION)
FIGURE 19: EUROPE LAB ON A CHIP MARKET, BY OTHER LAB ON A CHIP, 2018-2026 (IN $ MILLION)
FIGURE 20: EUROPE BIOCHIPS MARKET, BY PROTEIN CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 21: EUROPE PROTEIN CHIPS MARKET, BY DIAGNOSTICS, 2018-2026 (IN $ MILLION)
FIGURE 22: EUROPE PROTEIN CHIPS MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 23: EUROPE PROTEIN CHIPS MARKET, BY EXPRESSION PROFILING, 2018-2026 (IN $ MILLION)
FIGURE 24: EUROPE PROTEIN CHIPS MARKET, BY HIGH THROUGHPUT SCREENING, 2018-2026 (IN $ MILLION)
FIGURE 25: EUROPE PROTEIN CHIPS MARKET, BY PROTEOMICS, 2018-2026 (IN $ MILLION)
FIGURE 26: EUROPE PROTEIN CHIPS MARKET, BY OTHER PROTEIN CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 27: EUROPE BIOCHIPS MARKET, BY OTHER CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 28: EUROPE OTHER BIOCHIPS MARKET, BY CELL ARRAYS, 2018-2026 (IN $ MILLION)
FIGURE 29: EUROPE OTHER BIOCHIPS MARKET, BY TISSUE ARRAYS, 2018-2026 (IN $ MILLION)
FIGURE 30: EUROPE BIOCHIPS MARKET, BY GLASS, 2018-2026 (IN $ MILLIONS)
FIGURE 31: EUROPE BIOCHIPS MARKET, BY POLYMERS, 2018-2026 (IN $ MILLIONS)
FIGURE 32: EUROPE BIOCHIPS MARKET, BY SILICON, 2018-2026 (IN $ MILLIONS)
FIGURE 33: EUROPE BIOCHIPS MARKET, BY OTHER SUBSTRATE MATERIALS, 2018-2026 (IN $ MILLIONS)
FIGURE 34: EUROPE BIOCHIPS MARKET, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2026 (IN $ MILLIONS)
FIGURE 35: EUROPE BIOCHIPS MARKET, BY HOSPITALS AND DIAGNOSTICS CENTERS, 2018-2026 (IN $ MILLIONS)
FIGURE 36: EUROPE BIOCHIPS MARKET, BY ACADEMIC AND RESEARCH INSTITUTE, 2018-2026 (IN $ MILLIONS)
FIGURE 37: PORTER’S FIVE FORCE MODEL OF BIOCHIPS MARKET
FIGURE 38: VALUE CHAIN OF BIOCHIPS MARKET
FIGURE 39: KEY IMPACT ANALYSIS
FIGURE 40: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET, BY END-USER SEGMENT
FIGURE 41: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET, BY TYPE SEGMENT
FIGURE 42: EUROPE BIOCHIPS MARKET, REGIONAL OUTLOOK, 2017 & 2026 (IN %)
FIGURE 43: GERMANY BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 44: UNITED KINGDOM BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 45: FRANCE BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 46: ITALY BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 47: SPAIN BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 48: REST OF EUROPE BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 49: MARKET SHARE ANALYSIS OF KEY PLAYERS IN 2017 (%)
COMPANIES MENTIONED
1. AGILENT TECHNOLOGY INC.
2. BIOCHAIN INSTITUTE INC.
3. BIOMERIEUX SA
4. BIO-RAD LABORATORIES INC.
5. CEPHEID INC.
6. CYBRDI INC.
7. FLUIDIGM CORPORATION
8. GAMIDA FOR LIFE GROUP
9. ILLUMINA INC.
10. IMGENEX
11. MERCK GMBH
12. ORIGENE TECHNOLOGIES INC.
13. PERKINELMER INC.
14. SAMSUNG ELECTRONICS INC.
15. THERMO FISHER SCIENTIFIC INC.
FIGURE 1: EUROPE BIOCHIPS MARKET, BY END USERS, 2017 & 2026 (IN %)
FIGURE 2: EVOLUTION & TRANSITION OF BIOCHIPS
FIGURE 3: WORLDWIDE HEALTHCARE SPENDING, BY REGIONS, 2014-2015 (% OF GDP)
FIGURE 4: COMPARISON OF HEALTHCARE SPENDING PER CAPITA AND OUT OF THE POCKET HEALTH EXPENDITURE
FIGURE 5: EUROPE BIOCHIPS MARKET, BY DNA CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 6: EUROPE DNA CHIPS MARKET, BY AGRICULTURAL BIOTECHNOLOGY, 2018-2026 (IN $ MILLION)
FIGURE 7: EUROPE DNA CHIPS MARKET, BY CANCER DIAGNOSTICS & TREATMENT, 2018-2026 (IN $ MILLION)
FIGURE 8: EUROPE DNA CHIPS MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 9: EUROPE DNA CHIPS MARKET, BY GENE EXPRESSION, 2018-2026 (IN $ MILLION)
FIGURE 10: EUROPE DNA CHIPS MARKET, BY GENOMICS, 2018-2026 (IN $ MILLION)
FIGURE 11: EUROPE DNA CHIPS MARKET, BY SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING, 2018-2026 (IN $ MILLION)
FIGURE 12: EUROPE DNA CHIPS MARKET, BY OTHER CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 13: EUROPE BIOCHIPS MARKET, BY LAB ON A CHIP, 2018-2026 (IN $ MILLION)
FIGURE 14: EUROPE LAB ON A CHIP MARKET, BY CLINICAL DIAGNOSTICS, 2018-2026 (IN $ MILLION)
FIGURE 15: EUROPE LAB ON A CHIP MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 16: EUROPE LAB ON A CHIP MARKET, BY GENOMICS, 2018-2026 (IN $ MILLION)
FIGURE 17: EUROPE LAB ON A CHIP MARKET, BY POINT OF CARE (POC) & IN VITRO DIAGNOSIS (IVS), 2018-2026 (IN $ MILLION)
FIGURE 18: EUROPE LAB ON A CHIP MARKET, BY PROTEOMICS, 2018-2026 (IN $ MILLION)
FIGURE 19: EUROPE LAB ON A CHIP MARKET, BY OTHER LAB ON A CHIP, 2018-2026 (IN $ MILLION)
FIGURE 20: EUROPE BIOCHIPS MARKET, BY PROTEIN CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 21: EUROPE PROTEIN CHIPS MARKET, BY DIAGNOSTICS, 2018-2026 (IN $ MILLION)
FIGURE 22: EUROPE PROTEIN CHIPS MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 23: EUROPE PROTEIN CHIPS MARKET, BY EXPRESSION PROFILING, 2018-2026 (IN $ MILLION)
FIGURE 24: EUROPE PROTEIN CHIPS MARKET, BY HIGH THROUGHPUT SCREENING, 2018-2026 (IN $ MILLION)
FIGURE 25: EUROPE PROTEIN CHIPS MARKET, BY PROTEOMICS, 2018-2026 (IN $ MILLION)
FIGURE 26: EUROPE PROTEIN CHIPS MARKET, BY OTHER PROTEIN CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 27: EUROPE BIOCHIPS MARKET, BY OTHER CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 28: EUROPE OTHER BIOCHIPS MARKET, BY CELL ARRAYS, 2018-2026 (IN $ MILLION)
FIGURE 29: EUROPE OTHER BIOCHIPS MARKET, BY TISSUE ARRAYS, 2018-2026 (IN $ MILLION)
FIGURE 30: EUROPE BIOCHIPS MARKET, BY GLASS, 2018-2026 (IN $ MILLIONS)
FIGURE 31: EUROPE BIOCHIPS MARKET, BY POLYMERS, 2018-2026 (IN $ MILLIONS)
FIGURE 32: EUROPE BIOCHIPS MARKET, BY SILICON, 2018-2026 (IN $ MILLIONS)
FIGURE 33: EUROPE BIOCHIPS MARKET, BY OTHER SUBSTRATE MATERIALS, 2018-2026 (IN $ MILLIONS)
FIGURE 34: EUROPE BIOCHIPS MARKET, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2026 (IN $ MILLIONS)
FIGURE 35: EUROPE BIOCHIPS MARKET, BY HOSPITALS AND DIAGNOSTICS CENTERS, 2018-2026 (IN $ MILLIONS)
FIGURE 36: EUROPE BIOCHIPS MARKET, BY ACADEMIC AND RESEARCH INSTITUTE, 2018-2026 (IN $ MILLIONS)
FIGURE 37: PORTER’S FIVE FORCE MODEL OF BIOCHIPS MARKET
FIGURE 38: VALUE CHAIN OF BIOCHIPS MARKET
FIGURE 39: KEY IMPACT ANALYSIS
FIGURE 40: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET, BY END-USER SEGMENT
FIGURE 41: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET, BY TYPE SEGMENT
FIGURE 42: EUROPE BIOCHIPS MARKET, REGIONAL OUTLOOK, 2017 & 2026 (IN %)
FIGURE 43: GERMANY BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 44: UNITED KINGDOM BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 45: FRANCE BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 46: ITALY BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 47: SPAIN BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 48: REST OF EUROPE BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 49: MARKET SHARE ANALYSIS OF KEY PLAYERS IN 2017 (%)
COMPANIES MENTIONED
1. AGILENT TECHNOLOGY INC.
2. BIOCHAIN INSTITUTE INC.
3. BIOMERIEUX SA
4. BIO-RAD LABORATORIES INC.
5. CEPHEID INC.
6. CYBRDI INC.
7. FLUIDIGM CORPORATION
8. GAMIDA FOR LIFE GROUP
9. ILLUMINA INC.
10. IMGENEX
11. MERCK GMBH
12. ORIGENE TECHNOLOGIES INC.
13. PERKINELMER INC.
14. SAMSUNG ELECTRONICS INC.
15. THERMO FISHER SCIENTIFIC INC.
